Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV

The National Institute on Drug Abuse (NIDA) has issued Small Business Sources‑Sought Notice 75N95026R00007 (NAICS 541690) to identify qualified small‑business firms—including HUBZone, SDVOSB, 8(a), veteran‑, woman‑, and socially‑disadvantaged businesses—that can conduct a scientific analysis of glucagon‑like peptide‑1 receptor agonists (GLP‑1RAs) versus DPP‑4 inhibitors on alcohol and substance use disorder (ASUD) outcomes and HIV‑related health measures in people living with HIV (PLWH). Using Veterans Affairs electronic health record and pharmacy data, the selected vendor will extract medication exposure information, perform propensity‑score matching (1 exposed to up to 5 unexposed), and apply multivariable linear regression to assess pre‑ and post‑exposure changes in HIV and ASUD outcomes as directed by NIDA staff. Respondents must submit a detailed capability statement that addresses each project task, includes total employees, relevant personnel qualifications, any GSA Schedule or GWAC contracts, and confirms domestic sourcing (manufacturing location and NAICS size status per the Non‑Manufacturer Rule). The statement must also list the company name, SAM UEI, address, and both technical and administrative points of contact (name, title, phone, fax, email). Submissions are to be sent electronically in MS Word or PDF to Kim Harris (Kimberly.harris2@nih.gov) with the subject line “75N95026R00007” no later than 5:00 PM EST, 05 May 2026. Only firms that meet the applicable small‑business size standards should respond; non‑responsive or incomplete statements will be rejected.

Notice ID

df3e85dd8d924d86af74fcb7896efb6b

Solicitation Number

75N95026R00007

NAICS Code

541690

Classification Code

B529